Aiforia lands EU financing to develop AI-powered cancer detection

• EIB provides €20 million venture debt financing to Finnish life-science company Aiforia, to further develop its AI powered platform used in digital tissue analysis.
• Supported under the European Commission's InvestEU programme, the financing will accelerate Aiforia's product development and boost its commercial operations.
• Aiforia's deep learning artificial intelligence (AI) solutions can revolutionise diagnostic capabilities in image analysis, also enabling new medical discoveries.

The European Investment Bank (EIB) has signed a €20 million venture debt financing agreement with Finnish life-science technology innovator Aiforia. The funding will support the further development of the company's AI powered platform, designed to support pathologists in digital tissue analysis (digital pathology), notably for the detection of tumours. The software examines ultra-high-resolution images of biopsy samples to identify cancer cells with high precision and speed. The EIB backing for Aiforia is supported under the European Commission's InvestEU programme.

"Our continent is working to remain competitive, and we need to support the companies that make that possible." said EIB Vice-President Karl Nehammer. "From healthcare to digital life sciences, Europe must have the best technologies developed in-house to protect and care for its citizens. The solutions developed by Aiforia strengthen Europe's competitiveness, while giving an innovative EU company the opportunity to succeed on the global stage."

"We are pleased that the negotiations have led to the signing of a binding financing agreement." says Jukka Tapaninen, CEO of Aiforia. "The EIB venture debt financing strengthens Aiforia's financial position and supports the implementation of our strategy. With this financing, we can accelerate product development, expand our commercial operations internationally, and advance our goal of improving patient care through AI-powered image analysis solutions."

"This initiative under InvestEU is particularly welcome to Finland as it foments synergies of the Finnish high-tech clusters" added Elina Laurinen, Head of the European Commission Representation in Finland.

Aiforia plans to use the financing to accelerate its product development projects related to existing and new image analysis solutions, as well as to boost its commercial operations. The financing is divided into three tranches, with a first tranche of €5 million. Drawing each tranche necessitates achieving the revenue and other interim targets defined in the financing agreement. Aiforia and the EIB have also agreed on a synthetic warrant arrangement, which does not cause immediate share dilution for Aiforia's existing shareholders.

Background Information:

The European Investment Bank (EIB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 high-impact projects under eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investments union. Beyond long-term loans for large infrastructure, the EIB Group crowds in private investment for high-risk innovative projects and businesses, with a growing role in Europe's markets for venture debt, venture capital, guarantees and securitisations.

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable economy. It helps generate additional investment in line with EU policy priorities, including technological transformation, strategic investment, innovation, resilience, long-term competitiveness, and support for small and medium-sized enterprises InvestEU brings all EU financial instruments together under one roof, making funding for investment projects in Europe simpler, more efficient, and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub, and the InvestEU Portal. The InvestEU Fund is implemented through financial partners who invest in projects using the EU budget guarantee of €26.2 billion. This guarantee increases their risk-bearing capacity, thus mobilising at least €372 billion in additional investment. With top-ups from the Member State compartment and several EU initiatives, it has already mobilised €400 billion in public and private capital across the key priority sectors.

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia's diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Media and Investor Contacts:

Aiforia: Kaisa Helminen | +358 40 6790669 | [email protected]

European Commission: Ismo Ulvila | +358 50 541 1122 | [email protected]